Appeal type: unknown
Decision: unknown

he rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. You can find this rule at 42 CFR 422.101.The rules state that the following are NON-OPHTHALMOLOGIC INDICATIONS (includes cancer, chemotherapy and other conditions) of bevacizumab:Metastatic colorectal cancer-Used in combination with 5-fluorouracil-based chemotherapy as first-line or second-line therapy.-For the second-line treatment of patients with metastatic colorectal cancer who have progressed on a first-line Avastin-containing regimen when used in combination with fluoropyrimidine-irinotecan-or fluoropyrimidine-oxaliplatin-based chemotherapy.-Coverage is extended to use in combination with capecitabine (e.g., Xeloda).Non-small cell lung cancer-First-line treatment in combination with paclitaxel and carboplatin for unresectable, locally advanced, recurrent or metastatic non-squamous cell disease.-First-line treatment in combination with cisplatin -based or carboplatin-based regimens for recurrent or metastatic non-squamous cell disease.-Single agent continuation maintenance therapy if given first line with chemotherapy for recurrence or metastatic non-squamous cell disease in patients who achieve tumor response or stable disease following first-line chemotherapy.Metastatic breast cancer, HER2-negative, as first-line therapy in combination with paclitaxel.Central nervous system cancers -consider short-course single agent therapy for management of symptoms driven by RT necrosis poorly controlled vasogenic edema or mass effect: -Adult low-grade (WHO grade II) infiltrative supratentorial astrocytoma/oligodendroglioma;-Adult medulloblastoma;-Meningiomas;-Metastatic spine tumors;-Primary central nervous system lymphoma;-Recurrent anaplastic gliomas and glioblastoma multiforme of brain, as a single agent or in combination with irinotecan, carmustine/lomustine or temozolomide;-Recurrent adult intracranial and spinal ependymoma (excluding subependymoma).Metastatic renal cell carcinoma:-in combination with interferon alfa-2b as first-line therapy for predominant clear cell histology;-as a single-agent systemic therapy for non-clear cell histology; or-in combination with erlotinib or everolimus for selected patients with advanced papillary renal cell carcinoma including hereditary leiomyomatosis and renal cell cancer (HLRCC).Ovarian cancer:-Granulosa cell tumors, when malignant, after clinical relapse in patients with stage II-IV disease;-Epithelial ovarian, fallopian tube or primary peritoneal cancer for persistent disease or recurrence:;in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, for stage III or IV disease following initial surgical resection (Effective June 13,2018 based on (FDA) approval);;in combination with paclitaxel, pegylated liposomal doxorubicin or topotecan for the treatment of patients with platinum-resistant disease; in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent for the treatment of patients with platinum-sensitive disease (Effective December 06, 2016 based on (FDA) approval); or&#61607;a single agent.Cervical cancer:-in combination with either a) paclitaxel and cisplatin or b) paclitaxel and topotecan in persistent, recurrent, or metastatic disease; or-second-line therapy as a single agent for local/regional recurrence or distant metastases.Uterine neoplasms -endometrial carcinomaEpistaxis from Osler-Weber-Rendu(hereditary hemorrhagictelangiectasia (HHT)) syndromeMalignant pleural mesothelioma in combination with pemetrexed and cisplatin followed by single-agent maintenance therapy as:-treatment of unresectable or medically inoperable clinical stage I-III disease and tumors of epithelial or mixed histology; or-treatment of clinical stage IV disease or tumors of sarcomatoid histologySymptomatic post-radiation necrosis of the central nervous systemAIDS-related Kaposi sarcoma -subsequent systemic therapy given with antiretroviral therapy (ART) for relapsed/refractory advanced, cutaneous, oral, visceral, or nodal disease that has progressed on or not responded to first-line systemic therapy, and progressed on alternate first-line systemic therapy.Vulvar cancer-squamous cell carcinoma -in combination with cisplatin and paclitaxeYou can find these rules in the Local Coverage Article for Bevacizumab -Related to LCD L33394, A52370. This Local Coverage Article is effective for services provided on or after February 1, 2019 and before July 31, 2019.If you want to read these Medicare rules, you can go to this web site www.medicareappeal.com.The Plan contract says that the Plan covers items and services in accordance with Medicare rules.